ArticleEuropean heart journal. Case reports2025
Successful mitral-transcatheter edge to edge repair in a young patient with severe primary mitral regurgitation unsuitable for surgery: a case report.
Article in European heart journal. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mitral transcatheter edge-to-edge repair (M-TEER) is commonly performed in elderly patients with severe mitral regurgitation (MR) who are deemed high-risk for surgery. However, its application in younger patients remains limited. Case summary: We present the case of a 45-year-old male with a history of mitral valve prolapse, who developed severe MR due to chordal rupture. Surgical mitral valve repair was not considered feasible, and the patient successfully underwent M-TEER with implantation of two MitraClips XTW (Abbott Medical, USA), resulting in mild residual regurgitation and a mean mitral valve gradient of 5 mmHg. Discussion: This case highlights the potential role of M-TEER in selected young patients, expanding its indications beyond traditional cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.